Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients

Human Genome Variation

Volumn 3, Issue , 2016, Pages

  Mushiroda, Taisei ^a   Yanai, Hideki ^b,c   Yoshiyama, Takashi ^b,c   Sasaki, Yuka ^b   Okumura, Masao ^b   Ogata, Hideo ^b,c   Tokunaga, Katsushi ^d  

^a Institute of Physical and Chemical Research   (Japan)

^b Japan Anti Tuberculosis Association   (Japan)

^c RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; TUBERCULOSTATIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE (PEOPLE); LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 85028643495     PISSN: None     EISSN: 2054345X     Source Type: Journal    
DOI: 10.1038/hgv.2016.14     Document Type: Article

References (9)

1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland.
2. Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunogi M et al. Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis. Kekkaku 2008; 83: 13-19.
3. McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics 2014; 24: 409-425.
4. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007; 17: 383-390.
5. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicininduced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256-261.
6. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y et al. NAT2∗6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13: 6003-6008.
7. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
8. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
9. Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol 2013; 87: 2129-2139.